Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.57 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.57 |
| ▸ | F2 | P00734 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.50 |
| ▸ | GCGR | P47871 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979496 | 0.86 | CASP3 (0.77) | CASP3SENP8SENP7SENP6F2 | |
| SCHEMBL29784265 | 0.86 | CASP3 (0.77) | CASP3SENP8SENP7SENP6F2 | |
| SCHEMBL28947459 | 0.83 | HDAC6 (0.46) | F2MAPK14GCGRNAMPTHDAC6 | |
| SCHEMBL11565448 | 0.82 | CHEK2 (0.67) | CASP3SENP8SENP7SENP6F2 | |
| SCHEMBL164956 | 0.82 | CASP3 (0.57) | CASP3SENP8SENP7SENP6F2 | |
| SCHEMBL693160 | 0.82 | F2 (0.58) | CASP3SENP8SENP7SENP6F2 | |
| SCHEMBL11563588 | 0.82 | CASP3 (0.57) | CASP3SENP8SENP7SENP6F2 | |
| SCHEMBL3425755 | 0.81 | CASP3 (0.40) | CASP3SENP8SENP7SENP6MAPK14 | |
| SCHEMBL164967 | 0.81 | HPN (0.54) | CASP3SENP8SENP7SENP6F2 | |
| SCHEMBL7231465 | 0.81 | CASP3 (0.52) | CASP3SENP8SENP7SENP6MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1261601-B1 | SUBSTITUTED INDOLES FOR MODULATING NFKB ACTIVITY | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-29 | — | — | EP | disclosed |
| US-7342029-B2 | 2,3-Diphenyl-1H-indole-5-carboxylic acid; I kappa B kinase inhibitor; decrease activation of nuclear factor (NF) kappa B; antiinflammatory agent: arthritis, osteoarthritis, asthma, cardiac infarct, Alzheimer's disease, carcinomateous disorders or atherosclerosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-11 | — | — | US | disclosed |
| US-20050282866-A1 | 2,3-Diphenyl-1H-indole-5-carboxylic acid; I kappa B kinase inhibitor; decrease activation of nuclear factor (NF) kappa B; antiinflammatory agent: arthritis, osteoarthritis, asthma, cardiac infarct, Alzheimer's disease, carcinomateous disorders or atherosclerosis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-12-22 | — | — | US | disclosed |
| CN-1172929-C | substituted indoles | ���ĵ�˹ҩ��¹�����˾ | 2004-10-27 | — | — | CN | disclosed |
| US-20040209868-A1 | Substituted indoles | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-10-21 | — | — | US | disclosed |
| US-20030119820-A1 | Therapy of disorders resulting from increased activity of nuclear factor kappa-beta | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-06-26 | — | — | US | disclosed |
| EP-1261601-A1 | SUBSTITUTED INDOLES FOR MODULATING NFKB ACTIVITY | Aventis Pharma Deutschland GmbH (DE) | 2002-12-04 | — | — | EP | disclosed |
| CN-1379772-A | Substituted indoles for modulating NF kappa B activity | AVENTIS PHARMA GMBH (DE) | 2002-11-13 | — | — | CN | disclosed |
| WO-2001030774-A1 | SUBSTITUTED INDOLES FOR MODULATING NFKB ACTIVITY | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209868-A1 | Substituted indoles | NFKBIA, IKBKG, IKBKB | CASP3 2453/4885SENP8 3014/4885SENP7 2926/4885 |
| US-20030119820-A1 | Therapy of disorders resulting from increased activity of nuclear factor kappa-beta | NFKBIA, NFKB1, NFKB2 | CASP3 3078/4885SENP8 2908/4885SENP7 2880/4885 |
| US-20050282866-A1 | 2,3-Diphenyl-1H-indole-5-carboxylic acid; I kappa B kinase inhibitor; decrease activation of nuclear factor (NF) kappa B; antiinflammatory agent: arthritis, osteoarthritis, asthma, cardiac infarct, Alzheimer's disease, carcinomateous disorders or atherosclerosis | NFKBIA, IKBKB, IKBKE | CASP3 1791/4885SENP8 3865/4885SENP7 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.